Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

NCT03168035 is registered in ClinicalTrials.gov with NanoCarrier Co., Ltd. as lead sponsor.

NCT NCT03168035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
Lead sponsor
NanoCarrier Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
April 30, 2017
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, lymphoma